Abstract

Disrupted homeostasis of the microtubule binding protein tau is a shared feature of a set of neurodegenerative disorders known as tauopathies. Acetylation of soluble tau is an early pathological event in neurodegeneration. In this work, we find that a large fraction of neuronal tau is degraded by chaperone-mediated autophagy (CMA) whereas, upon acetylation, tau is preferentially degraded by macroautophagy and endosomal microautophagy. Rerouting of acetylated tau to these other autophagic pathways originates, in part, from the inhibitory effect that acetylated tau exerts on CMA and results in its extracellular release. In fact, experimental blockage of CMA enhances cell-to-cell propagation of pathogenic tau in a mouse model of tauopathy. Furthermore, analysis of lysosomes isolated from brains of patients with tauopathies demonstrates similar molecular mechanisms leading to CMA dysfunction. This study reveals that CMA failure in tauopathy brains alters tau homeostasis and could contribute to aggravate disease progression.

The tau protein has been implicated in neurodegenerative disorders and can propagate from cell to cell. Here, the authors show that tau acetylation reduces its degradation by chaperone-mediated autophagy, causing re-routing to other autophagic pathways and increasing extracellular tau release.

Details

Title
Acetylated tau inhibits chaperone-mediated autophagy and promotes tau pathology propagation in mice
Author
Caballero, Benjamin 1 ; Bourdenx Mathieu 2   VIAFID ORCID Logo  ; Luengo, Enrique 3 ; Diaz, Antonio 4 ; Sohn, Peter Dongmin 5 ; Chen, Xu 5 ; Wang, Chao 5   VIAFID ORCID Logo  ; Juste, Yves R 4 ; Wegmann, Susanne 6   VIAFID ORCID Logo  ; Patel, Bindi 4 ; Young, Zapporah T 7 ; Kuo, Szu Yu 7 ; Rodriguez-Navarro, Jose Antonio 8   VIAFID ORCID Logo  ; Shao Hao 7 ; Lopez, Manuela G 9   VIAFID ORCID Logo  ; Karch, Celeste M 10   VIAFID ORCID Logo  ; Goate, Alison M 11   VIAFID ORCID Logo  ; Gestwicki, Jason E 7   VIAFID ORCID Logo  ; Hyman, Bradley T 12   VIAFID ORCID Logo  ; Gan, Li 5 ; Cuervo, Ana Maria 4   VIAFID ORCID Logo 

 Albert Einstein College of Medicine, Department of Developmental and Molecular Biology, Bronx, USA (GRID:grid.251993.5) (ISNI:0000000121791997); Albert Einstein College of Medicine, Institute for Aging Studies, Bronx, USA (GRID:grid.251993.5) (ISNI:0000000121791997); Roche Chile Pharmaceuticals, Las Condes, Chile (GRID:grid.508828.f) 
 Albert Einstein College of Medicine, Department of Developmental and Molecular Biology, Bronx, USA (GRID:grid.251993.5) (ISNI:0000000121791997); Albert Einstein College of Medicine, Institute for Aging Studies, Bronx, USA (GRID:grid.251993.5) (ISNI:0000000121791997); Institut des Maladies Neurodégénératives, CNRS, Université de Bordeaux, Bordeaux, France (GRID:grid.462010.1) 
 Albert Einstein College of Medicine, Department of Developmental and Molecular Biology, Bronx, USA (GRID:grid.251993.5) (ISNI:0000000121791997); Albert Einstein College of Medicine, Institute for Aging Studies, Bronx, USA (GRID:grid.251993.5) (ISNI:0000000121791997); Universidad Autonoma de Madrid, Institute Teofilo Hernando for Drug Discovery, Department of Pharmacology, School of Medicine, Madrid, Spain (GRID:grid.5515.4) (ISNI:0000000119578126); Instituto de Investigación Biosanitaria Hospital de la Princesa, Madrid, Spain (GRID:grid.411251.2) (ISNI:0000 0004 1767 647X) 
 Albert Einstein College of Medicine, Department of Developmental and Molecular Biology, Bronx, USA (GRID:grid.251993.5) (ISNI:0000000121791997); Albert Einstein College of Medicine, Institute for Aging Studies, Bronx, USA (GRID:grid.251993.5) (ISNI:0000000121791997) 
 Weill Cornell Medicine, Helen and Robert Appel Alzheimer’s Disease Research Institute, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X) 
 Harvard Medical School, Massachusetts General Hospital, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany (GRID:grid.424247.3) (ISNI:0000 0004 0438 0426) 
 University of California at San Francisco, Institute for Neurodegenerative Disease, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811) 
 Albert Einstein College of Medicine, Department of Developmental and Molecular Biology, Bronx, USA (GRID:grid.251993.5) (ISNI:0000000121791997); Albert Einstein College of Medicine, Institute for Aging Studies, Bronx, USA (GRID:grid.251993.5) (ISNI:0000000121791997); Instituto Ramón y Cajal de Investigaciones Sanitarias Hospital Ramón y Cajal, Madrid, Spain (GRID:grid.411347.4) (ISNI:0000 0000 9248 5770) 
 Universidad Autonoma de Madrid, Institute Teofilo Hernando for Drug Discovery, Department of Pharmacology, School of Medicine, Madrid, Spain (GRID:grid.5515.4) (ISNI:0000000119578126); Instituto de Investigación Biosanitaria Hospital de la Princesa, Madrid, Spain (GRID:grid.411251.2) (ISNI:0000 0004 1767 647X) 
10  Washington University, Department of Psychiatry, St. Louis, USA (GRID:grid.4367.6) (ISNI:0000 0001 2355 7002) 
11  Icahn School of Medicine at Mount Sinai, Department of Neuroscience, New York, USA (GRID:grid.59734.3c) (ISNI:0000 0001 0670 2351) 
12  Harvard Medical School, Massachusetts General Hospital, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X) 
Publication year
2021
Publication date
2021
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2512386569
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.